LM320 - How to Start a cCMV Screening Program

Abstract:
Congenital cytomegalovirus (CMV) infection is the most common congenital infection in the US a leading cause of pediatric morbidity and developmental disabilities. This abstract outlines the implementation of a congenital CMV screening program aimed at early detection and intervention. The program focuses on newborn screening using PCR tests within the first three weeks of life. By implementing standardized protocols and training healthcare providers, cCMV screening programs aim to increase the number of infants screened allowing for timely treatment, and best outcomes for affected infants. This program will discuss hearing targeted, expanded targeted and universal screening processes.

Summary:
Establishing a Congenital Cytomegalovirus (cCMV) Screening Program: A Comprehensive Overview

Introduction
Congenital cytomegalovirus (cCMV) infection is recognized as a significant public health concern. cCMV is the leading infectious cause of neurological disabilities and hearing loss in children. With approximately 1 in 150 infants born with cCMV, early detection and intervention are crucial for improving long-term outcomes. This summary outlines the key components involved in establishing a cCMV screening program, emphasizing the importance of early diagnosis, community education, and effective treatment protocols.

Rationale for cCMV Screening
cCMV often goes undiagnosed at birth, leading to missed opportunities for early intervention. Infants are often asymptomatic at birth, but may manifest as hearing loss, developmental delays, or other serious complications later in life. The implementation of a cCMV screening program can facilitate timely diagnosis, allowing for early intervention and medical management. Early intervention can significantly improve developmental outcomes, making screening an essential aspect of pediatric care.

The presentation will outline the components of a successful cCMV screening program including:

Screening Protocols: We will discuss benefit of PCR (saliva or urine samples) collected within the first 21 days of life. This test is easy to perform with high sensitivity and specificity for detecting cCMV.

Training and Education: We will discuss the importance of healthcare provider training including obstetricians, pediatricians, and newborn hearing screening staff.

Referral and Follow-up Systems: We will discuss optimal way to track the babies who are positive for cCMV to ensure that babies have the follow up needed. This will include connections to specialists, audiologists, and developmental support services.

Challenges and Considerations
Implementing a cCMV screening program may present challenges, including funding, buy-in from healthcare providers, and addressing potential parental concerns about testing. It is essential to engage stakeholders throughout the planning and implementation phases to build support and facilitate a smooth rollout.

Conclusion
Establishing a cCMV screening program is an important step in improving the health outcomes of affected infants. By focusing on early detection, education, and comprehensive follow-up care, we hope to mitigate the long-term impacts of cCMV infection. Collaborative efforts among healthcare providers, families, and community organizations are important for the success, ultimately leading to better developmental trajectories for infants diagnosed with cCMV. Through this learning module, we hope to increase awareness, screening rates, and optimize follow up care for affected infants.

Brief Summary of Clinical Takeaways:
The clinical takeaway for this session in learning how to implement a cCMV screening at birth hospitals, pediatricians, or in Audiology clinics using best practices for early identification and treatment.